- Home
- AMAT vs ABBV Comparison
AMAT vs ABBV Comparison
Compare AMAT & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMAT | ABBV |
|---|---|---|
| Founded | 1967 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6B | 400.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AMAT | ABBV |
|---|---|---|
| Price | $307.73 | $220.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 20 |
| Target Price | ★ $241.48 | $239.16 |
| AVG Volume (30 Days) | ★ 6.5M | 5.8M |
| Earning Date | 02-12-2026 | 02-04-2026 |
| Dividend Yield | 0.61% | ★ 3.14% |
| EPS Growth | ★ 0.58 | N/A |
| EPS | ★ 8.66 | 1.32 |
| Revenue | $28,368,000,000.00 | ★ $59,644,000,000.00 |
| Revenue This Year | $3.75 | $10.38 |
| Revenue Next Year | $13.35 | $9.52 |
| P/E Ratio | ★ $34.78 | $166.65 |
| Revenue Growth | 4.39 | ★ 7.40 |
| 52 Week Low | $123.74 | $164.39 |
| 52 Week High | $302.78 | $244.81 |
Technical Indicators
Market Signals| Indicator | AMAT | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 71.47 | 42.76 |
| Support Level | $279.45 | $217.86 |
| Resistance Level | $298.22 | $237.04 |
| Average True Range (ATR) | 7.34 | 4.84 |
| MACD | 3.59 | -0.82 |
| Stochastic Oscillator | 96.70 | 11.55 |
Price Performance
Historical ComparisonAbout AMAT Applied Materials Inc.
Applied Materials is the largest semiconductor wafer fabrication equipment manufacturer in the world. It has a broad portfolio spanning nearly every corner of the WFE ecosystem. Applied Materials holds leading market share in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.